Fed’s Powell opens door to potential rate cuts at Jackson Hole
Investing.com - Cantor Fitzgerald maintained its Overweight rating and $132.00 price target on Disc Medicine (NASDAQ:IRON) on Wednesday. The company, currently trading at $58.18 with a market capitalization of $2 billion, has seen its stock deliver a 16.5% return over the past year despite significant volatility.
The research firm expressed confidence in the company’s program, stating that investors could profit from IRON based on this program alone, while considering other aspects as optional opportunities.
Cantor Fitzgerald noted that its financial model for Disc Medicine remains "very conservative" regarding patient numbers, despite feedback from the community suggesting potential strong demand for the company’s offerings.
The firm highlighted Disc Medicine’s sales strategy as a potential catalyst for "rapid cadence," though this remains contingent on reimbursement dynamics.
Disc Medicine is a biopharmaceutical company focused on developing treatments for hematologic diseases, with its stock maintaining the same Overweight rating from Cantor Fitzgerald that indicates expected outperformance relative to the market.
In other recent news, Disc Medicine announced its intention to submit a New Drug Application (NDA) for bitopertin, aimed at treating erythropoietic protoporphyria (EPP), in October 2025. This submission is planned under the FDA’s accelerated approval pathway, following positive feedback from a pre-NDA meeting with the agency. In a related development, Truist Securities initiated coverage on Disc Medicine with a Buy rating and set a price target of $86, citing the company’s promising hematological disorders pipeline as a key value driver. Meanwhile, Raymond (NSE:RYMD) James reiterated its Strong Buy rating on the company, maintaining a price target of $89, following Bristol Myers (NYSE:BMY) Squibb’s trial results for luspatercept. Although the trial narrowly missed its primary endpoint, the results showed meaningful improvements in red blood cell transfusion. Additionally, Disc Medicine appointed Nadim Ahmed to its board of directors, where he will serve as a class I director until the 2027 annual meeting of stockholders. Mr. Ahmed is also the President and CEO of Cullinan Therapeutics, bringing significant experience to the board. These developments highlight Disc Medicine’s ongoing strategic initiatives and potential growth in the biotech sector.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.